Ischemic stroke and atrial fibrillation-a deadlyserious combination

Cerebrovascular Diseases

Volumn 32, Issue 5, 2011, Pages 461-462

  Potpara, Tatjana S ^a   Lip, Gregory Y H ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; BRAIN ISCHEMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; NOTE; PRIORITY JOURNAL; RISK FACTOR; STROKE; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; STROKE;

EID: 80054066552     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000332030     Document Type: Note

References (20)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and reg iona l burden of d isease and risk factors, 20 01: systematic a nalysis of population health data. Lancet 2006; 367:1747-1757. (Pubitemid 43767064)
2. Feigin VL, Lawes CM, Bennett DA, Anderson CS: Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2:43-53. (Pubitemid 37443343)
3. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CF, MD, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209.
4. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation is an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-952. (Pubitemid 28446646)
6. Watson T, Shantsila E, Lip GYH: Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad rev isited. La ncet 2009; 373: 155-166.
7. Depta JP, Bhatt DL: Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost 2010; 104:657-663.
8. Karthikeyan G, Eikelboom JW: The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost 2010; 104:45-48.
9. Garcia DA, Lopes RD, Hylek EM: New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrom-botic drugs. Thromb Haemost 2010; 104:1099-1105.
10. Lip GY: Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103:683-685.
11. Tu HTH, Campbell BCV, Churilov L, Kalman JM, Lees KR, Lyden PD, Shuaib A, Donnan GA, Davis SM, on behalf of the VISTA collaborators: Frequent early cardiac complications contribute to worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2011;32:454-460.
12. Freudenberger RS, Schumaecker MM, Homma S: What is the appropriate approach to prevention of thromboembolism in heart failure? Thromb Haemost 2010; 103: 489-495.
13. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Qual it y of Ca re Outcomes in Research Interd isciplina ry Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-1711 (Pubitemid 46691097)
14. The European Stroke Organization Executive Committee and the ESO Writing Committee: Guidelines for the management of ischemic stroke and transient ischemic attack 2008. Cerebrovasc Dis 2008; 25:457-507.
15. Kamel H, Hegde M, Johnson DR, Gage BF, Clairborne JS: Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke. Stroke 2010; 41:1514-1520.
16. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby J V, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and morta lity in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026. (Pubitemid 37087616)
17. Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, Nam HS, Heo JH: Ischaemic cardiovascular mortality in patients with non-valvular atrial fibr illation according to CHADS2 score. T h romb Haemost 2011; 105: 712-720.
18. Rietbrock S, Plumb JM, Gallagher AM, van Staa TP: How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost 20 09; 101: 527-534.
19. Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, Babuty D, Charbonnier B: Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score = 1. Thromb Haemost 2010; 103: 833-840.
20. Ahrens I, Lip GYH, Peter K: New oral anticoagulant drugs in cardio-vascu lar disease. Thromb Haemost 2010; 10 4: 49-60.